Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Enhancing prescription drug innovation and adoption.

Alexander GC, O'Connor AB, Stafford RS.

Ann Intern Med. 2011 Jun 21;154(12):833-7, W-301. doi: 10.7326/0003-4819-154-12-201106210-00012.

2.
3.

Safe & sound. Interview by Helena Gail Rubinstein.

Woodcock J.

AHIP Cover. 2009 Mar-Apr;50(2):38-43. No abstract available.

PMID:
19385317
4.

FDA Regulation of Prescription Drugs.

Gassman AL, Nguyen CP, Joffe HV.

N Engl J Med. 2017 Feb 16;376(7):674-682. doi: 10.1056/NEJMra1602972. Review. No abstract available.

PMID:
28199811
5.

"Safer, but not safe enough".

Crombie HD.

Conn Med. 2006 Nov-Dec;70(10):645. No abstract available.

PMID:
17190395
6.

Comparison of prescription reimbursement methodologies in Japan and the United States.

Akaho E, MacLaughlin EJ, Takeuchi Y.

J Am Pharm Assoc (2003). 2003 Jul-Aug;43(4):519-26. Review.

PMID:
12952317
7.

Preventing postmarketing changes in recommended doses and marketing withdrawals.

Peck C.

Ernst Schering Res Found Workshop. 2007;(59):209-16. Review.

PMID:
17117726
8.

How drugs are developed and approved by the FDA: current process and future directions.

Ciociola AA, Cohen LB, Kulkarni P; FDA-Related Matters Committee of the American College of Gastroenterology..

Am J Gastroenterol. 2014 May;109(5):620-3. doi: 10.1038/ajg.2013.407. Review.

PMID:
24796999
9.

Prescription drugs, products liability, and preemption of tort litigation.

DeAngelis CD, Fontanarosa PB.

JAMA. 2008 Oct 22;300(16):1939-41. doi: 10.1001/jama.2008.513. No abstract available.

PMID:
18940985
10.

Canadian and US drug approval times and safety considerations.

Rawson NS, Kaitin KI.

Ann Pharmacother. 2003 Oct;37(10):1403-8.

PMID:
14519031
11.

The complexity of integrating speed and safety in drug development and approval.

Charo RA.

JAMA Intern Med. 2013 Jul 8;173(13):1165-6. doi: 10.1001/jamainternmed.2013.7161. No abstract available.

PMID:
23568604
12.
13.

Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.

Viscusi WK, Rowland SR, Dorfman HL, Walsh CJ.

Spec Law Dig Health Care Law. 1996 Mar;(205):9-52. No abstract available.

PMID:
10156421
14.

Parental preferences for FDA-approved medications prescribed for their children.

Yoon EY, Clark SJ, Butchart A, Singer D, Davis MM.

Clin Pediatr (Phila). 2011 Mar;50(3):208-14. doi: 10.1177/0009922810385105.

PMID:
21098519
15.
16.

Repairing the broken market for antibiotic innovation.

Outterson K, Powers JH, Daniel GW, McClellan MB.

Health Aff (Millwood). 2015 Feb;34(2):277-85. doi: 10.1377/hlthaff.2014.1003.

PMID:
25646108
17.

Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.

Jacobson JD, Feigal D.

Food Drug Law J. 2007;62(3):529-46. No abstract available.

PMID:
17915395
18.
19.

Safety in numbers--monitoring risk in approved drugs.

Okie S.

N Engl J Med. 2005 Mar 24;352(12):1173-6. No abstract available.

PMID:
15788493
20.

Can CER be an effective tool for change in the development and assessment of new drugs and technologies?

Brixner DI, Watkins JB.

J Manag Care Pharm. 2012 Jun;18(5 Supp A):S06-11.

PMID:
22663293
Items per page

Supplemental Content

Support Center